Skip to main content

Table 2 Demographic and baseline clinical characteristics of participants who took all the three doses of Eurartesim® and completed study procedures

From: Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania

  Main study Nested cohort Total n (%)
Variable N = 9,589 1,002 10,591
Country (n (%))    
Burkina Faso 2,718 (28. 3) 299 (29. 8) 3,017 (28. 5)
Ghana 4,119 (43. 0) 444 (44. 3) 4,563 (43. 1)
Mozambique 1,876 (19. 6) 89 (8. 9) 1,965 (18. 6)
Tanzania 876 (9. 1) 170 (17. 0) 1,046 (9. 9)
Gender (n (%))    
Female 5,068 (52. 8) 519 (51. 8) 5,587 (52. 7)
Male 4,521 (47. 2) 483 (48. 2) 5,004 (47. 3)
Age group (n (%))    
<6 4,654 (48. 5) 331 (33. 0) 4,985 (47. 1)
6 - <13 2,612 (27. 2) 398 (37. 7) 3,010 (28. 4)
13- <18 753 (7. 8) 112 (11. 2) 865 (8. 2)
>18 1,570 (16. 4) 161 (16. 1) 1,731 (16. 3)
Plasmodium positivity (n (%))    
RDT only 3,170 (33. 0) - 3,170(29. 9)
Microscopy only 1,405 (14. 6) 274 (27. 4) 1,679 (15. 9)
Both RDT and microscopy 4,984 (52. 0) 728 (72. 6) 5,712(53. 9)
Presumptive diagnosis 30 (0. 3) - 30 (0. 3)
*Parasite density (/μL) ( P. falciparum) * (n (%))    
No parasite observed 37 (0. 6) 8 (0. 8) 45 (0. 6)
<50 421 (6. 6) 80 (8. 0) 501 (6. 8)
50- < 500 1,282 (20. 1) 214 (21. 5) 1,496 (20. 3)
500- < 5,000 1,800 (28. 3) 265 (26. 6) 2,065 (28. 0)
5000- < 50,000 1,477 (23. 2) 268 (26. 9) 1,745 (23. 7)
≥50,000 1,354 (21. 2) 160 (16. 1) 1,514 (20. 6)
  1. *25 patients had other species of Plasmodium that was not falciparum.